尼拉帕利联合贝伐珠单抗对比尼拉帕利单药治疗铂敏感复发性卵巢癌
AVANOVA2是一项开放标签、随机、2期优效性试验,在丹麦、瑞典、芬兰、挪威和美国的15所大学医院入组97例铂敏感复发性高级别浆液性或子宫内膜样卵巢癌患者。
要点
- 联合组3级及以上不良事件65%,单药组45%;高血压和蛋白尿在联合组更常见。
- 该无化疗联合方案值得进一步评估,计划开展3期随机试验。
核心结论
- 在铂敏感复发性卵巢癌中,尼拉帕利联合贝伐珠单抗较尼拉帕利单药显著改善无进展生存期,支持进一步开展3期试验。
研究设计与样本
- 开放标签、随机、2期优效性试验,在丹麦、瑞典、芬兰、挪威和美国的15所大学医院入组97例铂敏感复发性高级别浆液性或子宫内膜样卵巢癌患者。
- 患者按1:1随机分配至尼拉帕利300 mg每日口服联合贝伐珠单抗15 mg/kg每3周静脉给药组(48例)或尼拉帕利单药组(49例),按同源重组缺陷状态和无化疗间期分层。
- 主要终点为研究者评估的无进展生存期,在意向治疗人群中分析;安全性在至少接受一剂研究药物的患者中分析。
主要发现
- 联合组3级及以上不良事件31例(65%),单药组22例(45%);两组最常见3级及以上不良事件均为贫血(7例[15%] vs 9例[18%])和血小板减少(5例[10%] vs 6例[12%])。
- 联合组高血压3级及以上10例(21%),单药组0例;任何级别蛋白尿联合组10例(21%),单药组0例;任何级别高血压联合组27例(56%),单药组11例(22%)。
- 未发生治疗相关死亡。
关键数值与推荐
- 入组患者年龄≥18岁,ECOG体能状态0-2,既往接受过含铂方案治疗原发疾病,复发后接受的非含铂方案≤1线;允许既往使用贝伐珠单抗或一线维持PARP抑制剂。
临床怎么用
- 对于铂敏感复发性卵巢癌,尼拉帕利联合贝伐珠单抗可作为无化疗治疗选择,但需关注高血压、蛋白尿及血液学毒性。
- 该方案为2期试验结果,尚待3期随机试验与化疗联合贝伐珠单抗对比验证。
局限性
- 这是一项2期、开放标签、样本量较小的试验,主要终点事件数有限,结果需3期试验确认。
- 随访时间较短,总生存数据尚未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity. Bevacizumab and maintenance poly(ADP-ribose) polymerase (PARP) inhibitors both significantly improve efficacy versus standard therapy, primarily in terms of progression-free survival, and offer the potential for chemotherapy-free treatment. AVANOVA2 compared niraparib and bevacizumab versus niraparib alone as definitive treatment for platinum-sensitive recurrent ovarian cancer. METHODS: This open-label, randomised, phase 2, superiority trial in 15 university hospitals in Denmark, Sweden, Finland, Norway, and the USA enrolled women aged 18 years or older with measurable or evaluable high-grade serous or endometrioid platinum-sensitive recurrent ovarian cancer. Patients had to have an Eastern Cooperative Oncology Group performance status of 0-2, and had to have previously received platinum-containing therapy for primary disease but ≤1 prior non-platinum-containing regimen for recurrent disease. Previous treatment with bevacizumab or first-line maintenance PARP inhibitors was permitted. Eligible patients were randomly assigned 1:1 (by random permuted blocks with block sizes of two and four, no masking), stratified by homologous recombination deficiency status and chemotherapy-free interval, to receive once-daily oral niraparib 300 mg alone or with intravenous bevacizumab 15 mg/kg once every 3 weeks until disease progression. The primary endpoint was progression-free survival, assessed by the investigators in the intention-to-treat population after events in at least 62 patients. Safety was analysed in all patients who received at least one dose of study drug. This ongoing trial is registered with ClinicalTrials.gov, number NCT02354131. FINDINGS: Between May 23, 2016, and March 6, 2017, 97 patients were enrolled and randomly assigned: 48 to niraparib plus bevacizumab and 49 to single-agent niraparib. Median follow-up was 16·9 months (IQR 15·4-20·9). Niraparib plus bevacizumab significantly improved progression-free survival compared with niraparib alone (median progression-free survival 11·9 months [95% CI 8·5-16·7] vs 5·5 months [3·8-6·3], respectively; adjusted hazard ratio [HR] 0·35 [95% CI 0·21-0·57], p<0·0001). Grade 3 or worse adverse events occurred in 31 (65%) of 48 patients who received niraparib plus bevacizumab and 22 (45%) of 49 who received single-agent niraparib. The most common grade 3 or worse adverse events in both groups were anaemia (7 [15%] of 48 vs 9 [18%] of 49) and thrombocytopenia (5 [10%] vs 6 [12%]), and hypertension in the combination group (10 [21%] vs 0). Niraparib plus bevacizumab was associated with increased incidences of any-grade proteinuria (10 [21%] of 48 patients vs 0) and hypertension (27 [56%] of 48 vs 11 [22%] of 49) compared with niraparib alone. No treatment-related deaths occurred. INTERPRETATION: The efficacy observed with this chemotherapy-free combination of approved agents in women with platinum-sensitive recurrent ovarian cancer warrants further evaluation. A randomised phase 3 trial investigating niraparib plus bevacizumab versus chemotherapy plus bevacizumab in platinum-sensitive recurrent ovarian cancer is planned. FUNDING: Nordic Society of Gynaecological Oncology and Tesaro.
引用
- Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019. PMID: 31474354. doi:10.1016/S1470-2045(19)30515-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。